Status:
COMPLETED
Impact of Exenatide on Sleep Duration
Lead Sponsor:
University of Chicago
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Brief Summary
This study investigates the effect of exenatide, a FDA approved medication for the treatment of type 2 diabetes on sleep duration and quality. Individuals with type 2 diabetes will be studied before a...
Eligibility Criteria
Inclusion
- Patients taking diabetes medications other then insulin will be included, but changes to their medications may be made as deemed necessary by their physician. Patients on stable medications for chronic and co-morbid conditions (high blood pressure, high cholesterol, etc) will be eligible
Exclusion
- Patients with moderate or severe kidney disease and history of pancreatitis or patients on insulin will be excluded, as Exenatide use is contraindicated or risky in these conditions.
- Patients with unstable cardiac, neurological or psychiatric disease and women who are pregnant or trying to get pregnant will be excluded. Patients who have severe COPD, severe neuropathy or chronic pain, which could impair sleep, will be excluded. Shift workers will be also excluded.
Key Trial Info
Start Date :
February 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 21 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT01416649
Start Date
February 1 2011
End Date
April 21 2021
Last Update
April 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637